McKesson's fourth-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.

At the American Urological Association annual meeting, several studies explored the potential role of surgery in managing ...

A new trial of patients with advanced rectal cancer has found that the addition of immunotherapy treatment alongside extended ...

Texas Radiotherapy expands their patients' services through their new medical group: Breast Associates of Texas. Breast Associates of Tex ...

Discover McKesson’s robust Q4 2025 growth with $359B revenue, key oncology acquisitions, and plans to unlock value via segment separation.

Welcome to McKesson's fourth quarter fiscal 2025 earnings conference call. Please be advised that today's conference is being recorded. At this time, I'd like to turn the call over to Jeni Dominguez, ...

The strong results of KEYNOTE-689 and likely FDA approval of pembrolizumab for perioperative HNSCC raise both concerns and ...

Springdale-based health system Northwest Health provided a total community benefit of more than $436 million in 2024, ...

The National Comprehensive Cancer Network (NCCN) policy summit, “Primary Care and Oncology Collaboration to Improve Patient ...

There is a promising shift toward non-surgical treatment strategies in early breast cancer, as clinicians aim to reduce harm without compromising care.

May 8, 2025 – Today, TIME reveals the second annual TIME100 Health list recognizing the 100 most influential individuals in ...

McKesson (NYSE:MCK) stock rises after hours with strong Q4 profits, a promising 2026 outlook, and plans to spin off its ...